Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07457359) titled 'Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer' on March 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Condition:
TNBC, Triple Negative Breast Cancer
Intervention:
Radiation: SBRT
Drug: Toripalimab (anti-PD-1 antibody)
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: January 4, 2026
Target Sample Size: 18
Countries of Recruitment:
China
To know...